Dato-DXd Plus Durvalumab Elicits Durable Responses in Metastatic TNBC Regardless of PD-L1 Status
November 22nd 2023
Peter Schmid, FRCP, MD, PhD, discusses the evaluation of combination of the datopotamab deruxtecan and durvalumab in patients with first-line triple-negative breast cancer, details safety and efficacy findings derived from the combination in the BEGONIA trial, and highlights ongoing efforts with this combination.